Hematopoietic Malignancies Flashcards
(27 cards)
Mature Lymphoid Neoplasms (3)
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Plasma Cell Neoplasm
Nodular Lymphocyte Predominant Hodgkins Lymphoma (NLPHL)
B-cell orgin and indolent. Minority of large lymphocytes with multilobated nuclei (“popcorn” cells); majority are reactive to lymphocytes and histiocytes.
Classical Hodgkins Lymphoma (Pertinent cells and Markers)
Based on RS cells (large, many or multilobed nucleus, eosinophilic inclusion-like nucleolus, CD30+ and CD15+, large cytoplasm, and ned for common leukocyte CD45)
Classical Hodgkins Lymphoma (Manifestations (4))
- Nodular Sclerosis: most common, effects young females, usually above the diaphragm, EBV in 10-25% , broad collagen bands and lacunar cells. 2) Mixed cellularity: 20-25% higher in kids and elderly, NO collagen bands, constituional B symptoms, EBV in 75%, below or both side of diaphragm. 3) Lymphocyte rich: 5% of CHL, RS cells present but rare. 4) Lymphocyte depleted: 1% of CHL (better prog.), no lymphocytes, numerous RS cells, some of which are anaplastic and bizzare (sarcomatous), and usually EBV+.
Types of Non-Hodgkin Lymphoma (4)
Burkitt lymphoma (GC B cell), follicular lymphoma (GC B cell), Mantle Cell Lymphoma (mantle cell), and SLL/CLL (pre or post GC, mature B cells)
Burkitt Lymphoma (GC B cell)
Aggressive; endemic (African, and jaw), sporadic (effects abdomen), starry sky pattern (tons of reactive cells surrounding macrophage), t(8;14) c-MYC (results in overexpression of cMYC, which results in a high proliferation index), CD10. CD19, CD20, BCL6, and MYC!, EBV in 30% sporadic cases.
Follicular Lymphoma (GC B cell)
40% of adult lymphoma, median age 60, indolent. Crowded follicles; node effacement, no mantle zone, polarity or starry sky. t(14;18) which causes overexpression of BCL2 and prevents apoptosis in cells that fail somatic mutation). CD10, CD19, CD20, BCL2!, and BCL6. Different from reactive follicularhyperplasia because variable follicle size, neg t(14;18) and neg BCL2.
Mantle Cell Lymphoma (mantle cell)
More in elderly and males; usu asymptomatic, effaced node, centroblst-like cells, characteristic t(11;14) (overexp. of BCL1, which increase CycD), CD19, CD20, CD5!, BCL1!, CD10, and BCL6 (neg for CD23)
SLL/CLL (pre or post GC, mature B cells)
CLL:blood lymphocytosis, BM involved, males and >65 years affected), most common leukemia of Western world. SLL: extramedullary site. Both: small round dense nuclei, with smudge cells, effaced nodes, 13q14 deletion in >50% of CLL. CD5, CD23!, CD19 (negative for CD10 or FMC7)
Plasma Cell Neoplasms Types (3)
Multiple/ Plasma Cell Myeloma, MGUS, and Plasmacytoma
Multiple/ Plasma Cell Myeloma
Usu >40 yrs, median age 68. CRAB symptoms (Hypercalcemia, renal insufficiency, anemia, and bone lesions), M spike meaning increase in immunoglobin, disturbs ionization of RBCs causes Rouleux formation on smear. Almost always need BM biopsy to diagnose; hypercellular with clockface chromatin and IgG inclusions. Lack antigenic diversity so more prone to infections.
Monoclonal Gammapathy of Undetermined Significance (MGUS)
M spike is present in protein electrophoresis, but no symptoms of Plasma Cell Myeloma. Have marrow plasmocytosis, no CRAB.
Plasmacytoma (Two types)
Solitary plasmacytoma of bone: local tumor of bone with multiple myeloma like cells (Diag: lesion in BONE, with PCM cells, no other lesions, no CRA, low/ no Mspike). Extraosseous plasmacytoma of bone: PCM-cell mass lesions outside of bone/ BM, usually in respiratory tract (75%); rare, median age 50 y w/ 2/3 favoring male.
Categories of AML
Congenital (cytogenetic findings), therapy related AML (t-AML), and AML,NOS
Congenital AML
RUNX1-RUNX1T1 t(8;21): RUNX! Encodes alpha subunit of CBF, good prognosis. CBFB-MYH11 inv(16) or t(16;16): see baso eos (immature eosinophils with baso granules), aka myelomonocytic leukemia, good prognosis, CBFB encodes beta subunit of CBF. PML-RARA t(15;17) aka PML: promyelocytes with faggot cells, RARA encodes for retinoic acid receptor alpha, can treat w/ ATRA and need to identify early because risk for DIC. MLL: bad prognosis. RBM15-MKL1 t(1;22): megaloblastic differentiation, often in infants with down syndrome; relatively good prognosis.
t-AML
Alkylating agent or radiation: 2-8 year latency period; whole or partial loss of Chr. 5 and 7. Topoisomerase II Inhibitors: 1-2 year latency period, often has rearrangement of MLL gene; poor prognosis.
AML, NOS
Molecular abnormalities: FLT3-ITD: poor prognosis, and trumps all. NPM1: good prognosis. CEBPA: good prognosis.
B-ALL
80-85% of ALL cases, CD19, CD22, and CD79a, lack CD20 of mature B cells. Three types: BCR-ABL t(9;22) (p190): more common in adults, worst prognosis of all AML (good prog in CML b/c of Gleevac). ETV6-RUNX1 t(12,21): 25% of childhood B-ALL, very favorable prognosis. MLL 11q23: common in neonates/ infants. Poor prognosis.
T-ALL
20-25% of ALL cases, CD2, CD3, CD7, CD99, and CD1a are markers. More in teenager males. May present with T-LBL w/ mediatinal mass), has better prognosis in children than adults.
Myelodysplastic Syndrome (MDS)- Characteristics and Types
Ineffective hematopoeisis and increased risk of progression to AML. Diagnosis: at least one peristent cytopenia, marrow findings with ring sideroblasts,, bilobed PMN, hypolobated small megakaryocytes. Two types: Primary/ Idiopathic (>50 y, insidious onset, w/ monosomy or delq Chr 5 and 7, trisomy 8) and Secondary/ Therapy-related (chemo drugs, B12/folic acid deficiency, virus, toxin, heavy metals, also related to t-AML with Chr 5 and 7 partial or whole deletion).
Low Grade MDS
Myeloblasts are less than 5% in BM. 1) RC-UD (good prog. Can specify further lineage, i.e. Refratory Neutropenia). 2) RC-MD (dysplasia in 2+ lineages w/ worst prognosis). 3) MDS with deletion 5q (associated with anemia, increased platelets, and marrow with distinctive megakaryocytes with small, round non-lobated nuclei).
High Grade MDS
Myeloblasts >5% of marrow cells. 1) Refractory Anemia with Excess Blasts (RAEB-1): 5-9% of blasts in marrow, median survival of 16 mo, with 25% progressing to AML. 2) Refractory Anemia Excess Blasts 2 (RAEB-2): 10-19% of blasts in marrow, median survival of 9 months, 33% transform to AML.
Myeloproliferative Neoplasms (Characteristics and Types)
Increase in one or more cell types (NO dysplasia), causes hypercellular marrow. Splenomegaly and/or hepatomegaly (sequestration and extramed. Hematopoiesis), can escalate to excessive marrow fibrosis leading to BM failure; can transform to acute leukemia or MDS). Types: CML, PV, PMF, and ET.
Chronic Myelogenous Leukemia (CML, a type of MPN)
Initial Phase: chronic; neutrophilia, BM hypercellularity, small megakaryocytes, no dysplasia. Blast Phase: transform to acute leukemia (AML or ALL) (>20% blast in marrow). BCR-ABL t(9;22) phil chr (p210) Tx w/ Imatinib, and dasatinib (2nd gen) PTKIs.